4.7 Article

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

Journal

BLOOD
Volume 112, Issue 10, Pages 4178-4183

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-06-165027

Keywords

-

Categories

Funding

  1. National Cancer Institute (NCI) [SPEC U01 CA114762]
  2. Penelope London Foundation
  3. Friedman Fund for Childhood Leukemia
  4. Walter Family Pediatric Leukemia Fund
  5. Pediatric Cancer Foundation [CA093552-02, NCI CA 51 001, CA 78 224, CA21765]
  6. National Institutes of Health (NIH)/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database [U01 GM61393, U01GM61374]
  7. NIH
  8. American Lebanese Syrian Associated Charities
  9. CureSearch

Ask authors/readers for more resources

The underlying pathways that lead to relapse in childhood acute lymphoblastic leukemia (ALL) are unknown. To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL, we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations (CNAs) in 20 diagnosis/relapse pairs relative to germ line. We identified 758 CNAs, 66.4% of which were less than 1 Mb, and deletions outnumbered amplifications by approximately 2.5:1. Although CNAs persisting from diagnosis to relapse were observed in all 20 cases, 17 patients exhibited differential CNA patterns from diagnosis to relapse. Of the 396 CNAs observed in 20 relapse samples, only 69 (17.4%) were novel ( absent in the matched diagnosis samples). EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort (25.0% and 35.0%, respectively), suggesting their role in disease recurrence. In addition, we noted concordance in global gene expression and DNA copy number changes (P = 2.2 x 10(-16)). Finally,relapse-specific focal deletion of MSH6 and, consequently, reduced gene expression were found in 2 of 20 cases. In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse. (Blood. 2008; 112: 4178-4183)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available